Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas
Primary Purpose
Basal Cell Carcinoma
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Laser treatment
SHAM-Treatment
Sponsored by
About this trial
This is an interventional treatment trial for Basal Cell Carcinoma focused on measuring basal cell carcinoma, laser surgery, pulsed dye laser, randomized controlled trial
Eligibility Criteria
Inclusion Criteria:
- histologically confirmed unpigmented sBCC on the trunk and extremities
- maximal tumour diameter 30 mm
Exclusion Criteria:
- Fitzpatrick skin type >III
- pregnancy
- previous BCC treatment within 4 weeks
- coagulation disorders
- photo sensitizing medication
- any indication of poor compliance
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Sham Comparator
Arm Label
Laser Treatment
SHAM Treatment
Arm Description
Pulsed dye laser 595nm
using the pulsed dye laser (PDL) laser without releasing a pulse
Outcomes
Primary Outcome Measures
complete response
Secondary Outcome Measures
patients satisfaction
questionnaire
side effects
questionnaire
reduction of tumor diameter and tumor thickness
Full Information
NCT ID
NCT02125669
First Posted
April 13, 2014
Last Updated
April 27, 2014
Sponsor
Hautklinik Darmstadt
Collaborators
University Medicine Greifswald
1. Study Identification
Unique Protocol Identification Number
NCT02125669
Brief Title
Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas
Official Title
The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
April 2014
Overall Recruitment Status
Completed
Study Start Date
November 2012 (undefined)
Primary Completion Date
September 2013 (Actual)
Study Completion Date
September 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hautklinik Darmstadt
Collaborators
University Medicine Greifswald
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Pulsed dye laser (PDL) treatments have been suggested to be a safe and effective therapeutic approach for treating basal cell carcinomas. Robust supporting evidence is, however, lacking due to inconsistent design of available studies. The purpose of this study is to evaluate the PDL's efficacy and safety in treating superficial basal cell carcinoma (sBCC) at low risk anatomical sites in an evidence based study setting.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Basal Cell Carcinoma
Keywords
basal cell carcinoma, laser surgery, pulsed dye laser, randomized controlled trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Laser Treatment
Arm Type
Active Comparator
Arm Description
Pulsed dye laser 595nm
Arm Title
SHAM Treatment
Arm Type
Sham Comparator
Arm Description
using the pulsed dye laser (PDL) laser without releasing a pulse
Intervention Type
Procedure
Intervention Name(s)
Laser treatment
Intervention Description
Pulsed dye laser 595nm
Intervention Type
Device
Intervention Name(s)
SHAM-Treatment
Intervention Description
using the pulsed dye laser (PDL) laser without releasing a pulse
Primary Outcome Measure Information:
Title
complete response
Time Frame
9 months
Secondary Outcome Measure Information:
Title
patients satisfaction
Description
questionnaire
Time Frame
9 months
Title
side effects
Description
questionnaire
Time Frame
9 months
Title
reduction of tumor diameter and tumor thickness
Time Frame
9 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
histologically confirmed unpigmented sBCC on the trunk and extremities
maximal tumour diameter 30 mm
Exclusion Criteria:
Fitzpatrick skin type >III
pregnancy
previous BCC treatment within 4 weeks
coagulation disorders
photo sensitizing medication
any indication of poor compliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maurizio Podda, Dr.
Organizational Affiliation
Hautklinik Darmstadt
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Syrus Karsai, Dr.
Organizational Affiliation
Hautklinik Darmstadt
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Heiko Friedl
Organizational Affiliation
Hautklinik Darmstadt
Official's Role
Study Chair
12. IPD Sharing Statement
Learn more about this trial
Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas
We'll reach out to this number within 24 hrs